Generics 1

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Imatinib mesylate manufacturers

1 products found

Filters

Filters

Filters , active

Country of origin : Lebanon

Clear all

1 products found

imatinib mesylate

Tablets, film coated 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Lebanon
GMP approvals
Lebanon
Manufacturer #28777

Want to see all 1 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Imatinib Mesylate

Imatinib Mesylate is used to treat certain types of leukaemia, type of cancers that begins in the white blood cells, other cancers and disorders of the blood cells. Imatinib is also used to treat certain types of gastrointestinal stromal tumours, a type of tumour that grows in the walls of the digestive passages and may spread to other parts of the body. Imatinib is also used to treat tumours that forms under the top layer of skin, especially when the tumour cannot be removed surgically, has spread to other parts of the body, or has come back after surgery. Imatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Imatinib is sold under the brand name Gleevec among others.
Scientists at Ciba-Geigy (which merged with Sandoz in 1996 to become Novartis) invented Imatinib in the late 1990s, in a team led by biochemist Nicholas Lydon and that included Elisabeth Buchdunger and Jürg Zimmermann.

Forms and Dosage

It is sold in the tablet form in 100mg, 400mg strengths, in the treatment of Acute Lymphoblastic Leukaemia, the Indicated dosage for adults is 600 mg per day. In the treatment of Myelodysplastic/Myeloproliferative Diseases, the standard adult dose is 400 mg. in the treatment of Chronic Eosinophilic Leukemia, 100 mg which may increase to 400 mg. for treating Mastocytosis, the Indicated dosage for adults with aggressive systemic mastocytosis is 400 mg PO qDay and for Gastrointestinal Stromal Tumors, 400 mg

The cost of Imatinib Mesylate

The wholesale cost in the developing world is about US$1,386.49–19,162.50 a year. Whereas In the United States a typical dose for a year has a wholesale cost of $84,408, while in the United Kingdom the NHS was paying about £20,980 ($27,973) in 2016. Prices for a 100 mg pill of Gleevec internationally range from $20 to $30, although generic Imatinib is cheaper, as low as $2 per pill.

How does Imatinib Mesylatework?

Imatinib is a cancer growth blocker called a tyrosine kinase inhibitor. These inhibitors are proteins that cells use to signal to each other to grow. There are a number of different tyrosine kinases and blocking them stops the cancer cells growing. Imatinib targets different tyrosine kinases, depending on the type of cancer.

Finding Imatinib Manufacturers and Suppliers

The process of finding trusted Imatinib manufacturers and Imatinib suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of Imatinib . The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation